Previous 10 | Next 10 |
Shares of Ultragenyx Pharmaceutical ( RARE ) have risen by 37% since my January update recommended readers establish a pilot position and accumulate dips in the near term as a turnaround appeared likely. Now that the stock has pulled back from highs last seen in April, I'm looking forward ...
Mirth is like a flash of lightning that breaks through a gloom of clouds and glitters for a moment. ” ― Joseph Addison Today, we look at a small RNA developmental concern whose stock has had a nice run over the past few weeks. Can the rally continue? We take an in-depth inve...
Mirth is like a flash of lightning that breaks through a gloom of clouds and glitters for a moment. ” ― Joseph Addison Today, we look at a small RNA developmental concern whose stock has had a nice run over the past few weeks. Can the rally continue? We take an in-depth inve...
Ultragenyx Pharmaceutical ( RARE ) and Arcturus Therapeutics ( ARCT +37.7% ) say they will expand their licensing deal and research collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets. More news on: Ultragenyx Pharmaceutical Inc., Ar...
Scope of the collaboration expands to include up to 12 rare disease targets and includes Arcturus nucleic acid technologies to enable mRNA, DNA, and siRNA therapeutics $30 million of upfront payments to Arcturus, including $6 million cash for collaboration agreement amendment an...
Ultragenyx Pharmaceutical (NASDAQ: RARE ) has promoted Erik Harris to Executive Vice President and Chief Commercial Officer (CCO), effective June 11. More news on: Ultragenyx Pharmaceutical Inc., Healthcare stocks news, Read more ...
NOVATO, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced it has promoted Erik Harris to Executive Vice President...
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with this Read more ...
NOVATO, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that the Biotechnology Innovation Organization (BIO) has...
NOVATO, Calif., May 10, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp, the company’s Chief Financial...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...